Prophylaxis against transplant rejection

Clinical trials for Prophylaxis against transplant rejection

9 trials across Europe

See all trials →

Quick filters

9 Clinical trials

Prophylaxis against transplant rejection

Not yet recruiting

Study on Siplizumab, Cyclophosphamide, and Splenectomy for Preventing Liver Transplant Rejection in Patients Receiving a Deceased Donor Liver

InvestigationalNo placebo

Study on Siplizumab, Cyclophosphamide, and Splenectomy for Preventing Liver Transplant Rejection in Patients Receiving a Deceased Donor Liver

InvestigationalNo placebo

Sweden

Participants:18–64 years · 65+ years
Substances:Siplizumab
Sponsor:Itb-Med AB

Contact Research Centre

Prophylaxis against transplant rejection

Not recruiting

Long-Term Follow-Up Study of TX200-TR101 for Patients with Kidney Transplant Rejection

InvestigationalNo placebo

Long-Term Follow-Up Study of TX200-TR101 for Patients with Kidney Transplant Rejection

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:TX200-TR101
Sponsor:Sangamo Therapeutics Inc.

Contact Research Centre

Prophylaxis against transplant rejection

Not recruiting

Study Comparing Tacrolimus Formulations for Preventing Liver Transplant Rejection in New Adult Recipients

Registered drugNo placebo

Study Comparing Tacrolimus Formulations for Preventing Liver Transplant Rejection in New Adult Recipients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Tacrolimus
Sponsor:Universitaetsklinikum Regensburg AöR

Contact Research Centre

Prophylaxis against transplant rejection

Not recruiting

Study on Siplizumab and Rabbit Anti-Thymocyte Globulin for Preventing Rejection in New Kidney Transplant Patients

Registered drugNo placebo

Study on Siplizumab and Rabbit Anti-Thymocyte Globulin for Preventing Rejection in New Kidney Transplant Patients

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Paracetamol
Sponsor:Itb-Med AB

Contact Research Centre

Prophylaxis against transplant rejection

Not recruiting

Study on the Safety of TX200-TR101 for Preventing Kidney Transplant Rejection in Patients Receiving a Living Donor Transplant

InvestigationalNo placebo

Study on the Safety of TX200-TR101 for Preventing Kidney Transplant Rejection in Patients Receiving a Living Donor Transplant

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:TX200-TR101
Sponsor:Sangamo Therapeutics France

Contact Research Centre

Prophylaxis against transplant rejection

Not recruiting

Study Comparing Tacrolimus Levels in Children with Organ Transplants Switching from Prograf to Advagraf

Registered drugNo placebo

Study Comparing Tacrolimus Levels in Children with Organ Transplants Switching from Prograf to Advagraf

Registered drugNo placebo

Czechia

Participants:0–17 years
Substances:Tacrolimus
Sponsor:Astellas Pharma Europe Limited